Login to Your Account

GPC Partners Satraplatin With Pharmion For Potential $270M

By Karen Pihl-Carey

Wednesday, December 21, 2005
Days after handing to the FDA the first parts of a rolling new drug application for satraplatin, GPC Biotech AG found an ex-U.S. marketing partner for the oral platinum-based compound, which is in development to treat hormone-refractory prostate cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription